Marksans Pharma
MARKSANSNSE

Marksans Pharma

₹252.7516.69 (7.07%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
237.02
Today’s high
254.00
52 week low
155.00
52 week high
270.70
Open price
238.95
Previous close
236.06
Live volume
68,01,842
Lower circuit
202.20
Upper circuit
303.30

Fundamentals

Market Cap
₹10,697Cr
ROE
13.82%
P/E Ratio(TTM)
25.46
EPS(TTM)
9.27
P/B Ratio
3.54
Dividend Yield
0.00%
Industry P/E
33.71
Book Value
66.71
Debt to Equity
0.11
Face Value
1

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹891
+15.07%
Profit (Cr)
₹149
+31.08%
02505007501k
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+23%
3Y CAGR+21%
Profit growthValue
1Y (TTM)+64%
3Y CAGR+27%

About

Marksans Pharma is a trusted global pharmaceutical company that develops, manufactures, and distributes both over-the-counter (OTC) and prescription (Rx) drugs for regulated markets. Its guiding vision is to transform into a respected, profitable, and integrated global pharmaceutical enterprise by delivering quality formulations to people. The company's overall manufacturing capacity has impressively reached 26 billion units per year, a fourfold increase achieved over several years.;
CEO/MD
NA
Founded in
--
NSE symbol
MARKSANS

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
43.87%
Retail And Others
32.79%
Foreign Institutions
16.76%
Mutual Funds
4.66%
Other Domestic Institutions
1.91%

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹8,453.00
+109.50 (1.31%)
L
    H
    20,958.50111.7624.01
    PfizerPFIZER
    ₹4,592.50
    +64.60 (1.43%)
    L
      H
      20,728.7528.694.93
      ₹765.05
      -1.30 (0.17%)
      L
        H
        19,006.0231.953.74
        ₹1,373.70
        +8.60 (0.63%)
        L
          H
          18,915.1329.214.85
          Livesquawk
          Marksans Pharma plans to launch 50 products in the U.S. by FY '27. R&D spend to remain 3% of revenue; Europe, Canada contributions expected FY '27.
          Livesquawk
          Marksans Pharma aims to boost its North American business by enhancing store brand presence. The company targets doubling OTC revenue from U.S. store brands.
          2026
          26
          May
          Quarterly & Annual Result
          Release date
          5
          Feb
          Quarterly Result
          Release date
          2025
          13
          Nov
          Quarterly Result
          Release date
          12
          Aug
          Quarterly Result
          Release date

          1
          Aug
          Dividend
          Ex date
          ₹0.80
          per share

          For each share you hold, you will receive ₹0.80
          Dividend amount₹0.80 per share
          Dividend TypeFinal
          Ex Date1 Aug ‘25
          Record Date1 Aug ‘25
          Announcement date19 May ‘25

          19
          May
          Dividend
          Announced
          ₹0.80
          per share

          For each share you hold, you will receive ₹0.80
          Dividend amount₹0.80 per share
          Dividend TypeFinal
          Ex Date1 Aug ‘25
          Record Date1 Aug ‘25
          Announcement date19 May ‘25
          2024

          17
          Sep
          Dividend
          Ex date
          ₹0.60
          per share

          For each share you hold, you will receive ₹0.60
          Dividend amount₹0.60 per share
          Dividend TypeFinal
          Ex Date17 Sep ‘24
          Record Date17 Sep ‘24
          Announcement date30 May ‘24
          Events calendar
          View upcoming events in other stocks